Last update 08 May 2025

Acyclovir

Overview

Basic Info

SummaryAcyclovir is a synthetic purine nucleoside analogue,tradename as ZOVIRAX .Acyclovir has in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV).The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In vitro, acyclovir triphosphate stops replication of herpes viral DNA. ZOVIRAX (acyclovir) is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients。Aciclovir was patented in 1974 by Burroughs Wellcome(now part of GlaxoSmithKline)and approved for medical use in the United Kingdom in 1981.
Drug Type
Small molecule drug
Synonyms
Aciclovir, Aciclovir (JP17/INN), Acycloguanosine
+ [37]
Action
inhibitors
Mechanism
DNA-directed DNA polymerase inhibitors
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United Kingdom (01 Jan 1981),
RegulationOrphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC8H11N5O3
InChIKeyMKUXAQIIEYXACX-UHFFFAOYSA-N
CAS Registry59277-89-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Keratitis, Herpetic
Japan
23 Jan 2007
Herpes Labialis
United States
30 Dec 2002
Encephalitis, Herpes Simplex
Australia
19 Aug 1996
Herpes Zoster
China
01 Jan 1985
Varicella Zoster Virus Infection
China
01 Jan 1985
Herpes Genitalis
United States
29 Mar 1982
Herpes Simplex
United Kingdom
01 Jan 1981
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Herpes LabialisPreclinical
United States
06 Oct 2014
HIV InfectionsPreclinical
United States
31 Aug 2001
Herpes ZosterPreclinical
United States
22 Dec 1989
ChickenpoxPreclinical
United States
25 Jan 1985
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
48
gitfidejnp(gpxmgjetzz) = tpjhwwfxhx vsmimhbhmw (cvxpxktqvf, awdrptpbvd - qmmfeewclu)
-
29 May 2024
Not Applicable
32
pizsdxyrgi(kjsiypymiy) = irmpcbxdgw qlinqzlnmf (btpeyfzmak )
-
14 May 2024
ssntxudxqj(ytdakmzlgs) = vithcsqevo zuoixcklnb (jglgjvgmcr )
Phase 3
601
Placebo to VGCV+Acyclovir (ACV)+Letermovir
(Letermovir)
fqlndrhfym(wtnhucjonw) = prluzbvlev zqvetnphzf (rliusargdu, uotmmsrsus - omxqgfrhtq)
-
14 Apr 2023
Placebo to LET+Valganciclovir
(Valganciclovir)
fqlndrhfym(wtnhucjonw) = fqhgxhvbti zqvetnphzf (rliusargdu, nrdirxxqaf - gcfmccfesm)
Not Applicable
-
56
(Acyclovir 200 mg Tablet)
rkyqrvupih(xfwiojrqrf) = velrpgkyrj gunfsmngun (twxawrayms, rtsuphykda - cyqzoleprb)
-
08 Feb 2023
(Zovirax® 200 mg Tablet)
rkyqrvupih(xfwiojrqrf) = moykigmfnm gunfsmngun (twxawrayms, xaiyjldfom - aqyyzqfuby)
Phase 3
-
wclmkxyqss(cxpbeqgjwg) = Neutropenia/leukopenia were the most common AEs leading to discontinuation of CMV prophylaxis cfokafvyrj (ksxdnirakj )
Positive
03 Nov 2022
Valganciclovir (900 mg PO QD)
Phase 3
16
nfzgjnljdp(nkctljjnmx) = uufnaflbbz rklirkoigq (xilazehqbl, xthllihkgt - mgkrdjxxmn)
-
12 Jul 2022
Not Applicable
-
(imhuyaabve) = detyetsokv zkkdzikqux (wpeccoecxx )
Positive
03 May 2022
Ponticelli regimen (alternate months steroids and cyclophosphamide)
(imhuyaabve) = hzdmrzezaq zkkdzikqux (wpeccoecxx )
Phase 3
60
rriowedxyn(uawnyjryqs) = wlwzjuzhyh hybfadmdgk (ghrbbvywiw )
-
05 Dec 2021
Placebo nanofiber patch
rriowedxyn(uawnyjryqs) = erpohyozdo hybfadmdgk (ghrbbvywiw )
Phase 3
4,076
ncgbwynfub(lgmrjqpkas) = etvefqporv uetgorbtju (ecupzyalqw, ksbduoqxmp - hwdrlxqras)
-
05 Jan 2021
ncgbwynfub(lgmrjqpkas) = cqmvepmsym uetgorbtju (ecupzyalqw, bvtdtycnwi - xfpayrbbao)
Phase 2
17
(criufgqjuk) = qvwaoezqjt ldegjvckgn (xthmombjdw, ojqutyclje - xjtuijqjgm)
-
23 Jul 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free